Sandu Pharmaceuticals Profit & Loss Annual

BSE: 524703 | NSE: - | ISIN: INE751D01014 | Sector: Biotechnology & Drugs

50.37 -2.94 (-5.51%)Updated : 25 Apr 2025

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	67.28	65.35	65.50	58.76
Total Revenue	67.28	65.35	65.50	58.76
Costof Revenue Total	32.57	31.19	35.74	34.50
Gross Profit	34.71	34.16	29.76	24.26
Selling/ General/ Admin Expenses Total	10.07	11.10	8.91	8.14
Depreciation/ Amortization	0.58	0.52	0.53	0.56
Unusual Expense( Income)	0.00	0.00	0.00	-
Other Operating Expenses Total	22.34	20.58	17.97	13.95
Total Operating Expense	65.57	63.38	63.16	57.15
Operating Income	1.71	1.97	2.34	1.60
Interest Inc( Exp) Net- Non- Op Total	-0.02	-0.02	-0.03	-0.03
Other Net	0.38	0.27	0.01	0.11
Net Income Before Taxes	2.07	2.22	2.32	1.68
Provisionfor Income Taxes	0.61	0.70	0.73	0.59
Net Income After Taxes	1.46	1.52	1.59	1.09
Net Income Before Extra Items	1.46	1.52	1.59	1.09
Net Income	1.46	1.52	1.59	1.09
Total Adjustmentsto Net Income	0.00	-	0.00	-
Income Availableto Com Excl Extra Ord	1.46	1.52	1.59	1.09
Income Availableto Com Incl Extra Ord	1.46	1.52	1.59	1.09
Diluted Net Income	1.46	1.52	1.59	1.09
Diluted Weighted Average Shares	0.97	0.94	0.85	0.71
Diluted EPS Excluding Extra Ord Items	1.51	1.61	1.87	1.54
DPS- Common Stock Primary Issue	0.80	0.75	0.75	0.00
Diluted Normalized EPS	1.51	1.61	1.87	1.54
period Length	12.00	12.00	12.00	12.00
period Type	-	-	-	-